Inhibitors | Comment | Organism | Structure |
---|---|---|---|
fumonisin B1 | - |
Mus musculus |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
membrane | membrane-associated | Mus musculus | 16020 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | Q9D6K9 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
epithelium | - |
Mus musculus | - |
lung | LASS5 is the predominant ceramide synthase isoform detected in lung epithelia | Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
LASS5 | - |
Mus musculus |
longevity assurance homolog 5 | - |
Mus musculus |
Organism | Comment | Expression |
---|---|---|
Mus musculus | pulmonary LASS5 is developmentally regulated, but its expression is spatially and gender nonspecific | additional information |
General Information | Comment | Organism |
---|---|---|
physiological function | exogenously expressed LASS5 in lung epithelia triggers increased ceramide synthesis, knockdown studies using fumonisin B1 or LASS5 siRNA reduce ceramide synthase activity by 78% or 45%, respectively. Overexpression of LASS5 also reduces phosphatidylcholine synthesis. Maximal inhibition is achieved when LASS5 is coexpressed with a plasmid encoding a neutral sphingomyelinase involved in sphingomyelin hydrolysis | Mus musculus |